Atopic Dermatitis

Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.

Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.

Topline results for the topical sodium channel blocker are expected in 2024.

Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

A poster presentation from SCALE 2023 evaluated the use of ceramide-containing skin care products with prescription treatments for a healthy skin barrier.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.

New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.

Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.

Patients with atopic dermatitis were asked to rate the importance of several factors that may influence their decision to participate in a clinical trial.

Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

Adam Friedman, MD, FAAD, discusses his RAD 2023 session, "Using Teledermatology to Reduce Disparities in Atopic Dermatitis."

Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.

Catch up on all coverage from Revolutionizing Atopic Dermatitis.

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.